icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 22-25, 2016, Boston MA
Back grey_arrow_rt.gif
Tolerability and Acceptability of Cabotegravir
LA Injection: Results From the ECLAIR Study
  Reported by Jules Levin
CROI 2016 Feb 22-14 Boston
Miranda Murray,1 Martin Markowitz,2 Ian Frank,3 Robert M. Grant,4 Kenneth H. Mayer,5 David A. Margolis,6 Krischan J. Hudson,6 Britt S. Stancil,7 Susan L. Ford,7 Alex R. Rinehart,6 William R. Spreen6
1ViiV Healthcare, London, UK; 2The Aaron Diamond AIDS Research Center, an affiliate of the Rockefeller University, New York, NY; 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 4Institute of Virology & Immunology, Gladstone Institutes, San Francisco, CA; Department of Medicine, University of California, San Francisco, CA; 5The Fenway Institute, Fenway Health, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston, MA; 6ViiV Healthcare, Research Triangle Park, NC; 7PAREXEL International (formerly employed by GlaxoSmithKline), Research Triangle Park, NC